MAYO CLINIC LABORATORIES

1-800-533-1710

MYD88

MYD88, L265P, Somatic Gene Mutation, DNA Allele-Specific PCR, Varies

Patient ID	Patient Name		Birth Date	Gender	Age
SA00091632	TESTINGRNV, REPORT		1999-11-11	M	17
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00091632	SA00091632	CLIENT, CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		02 Jun 2017 06:00			

MYD88 L265P Gene Mutation Analysis

Specimen Type

MCR

Peripheral blood

Final Diagnosis

[1] MCR

Peripheral blood, MYD88 L265P Mutation Analysis, Allele-specific PCR:

Positive for MYD88 L265P alteration.

Comment: The MYD88 L265P abnormality is highly associated (>90%) with the pathologic diagnosis of lymphoplasmacytic lymphoma and the clinical syndrome of Waldenstrom macroglobulinemia (LPL/WM), particularly in the setting of an elevated IgM serum monoclonal paraprotein. A positive molecular result therefore supports the possibility of LPL/WM; however, this mutation has also been reported in other B-cell neoplasms, including IgM monoclonal gammopathy of uncertain significance, a small subset of marginal zone lymphomas (approximately 10%). The MYD88 L265P mutation is also identified in some diffuse large B-cell lymphomas (DLBCL), with a higher prevalence observed in "immune privileged" sites (e.g. central nervous system, testis, breast, skin). Clinical, laboratory and pathologic correlation is required for final diagnosis and interpretation of these results. The analytical sensitivity of this assay is approximately 1% mutation detection in a wild type background.

Signing Pathologist: Melissa Tricker-Klar

ADDITIONAL INFORMATION

DNA was extracted from the specimen and subjected to allele-specific polymerase chain reaction (PCR) using an allele specific forward primer that distinguishes the presence of the MYD88 L265P mutation. The reaction also contains a wild-type forward 5' of the mutation site and a single reverse primer. Expected fragment lengths of PCR products are interpreted using capillary electrophoresis.

Received: 02 Jun 2017 15:25 **Reported:** 02 Jun 2017 15:56

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292